Phase III clinical trial - Appareil pulmonaire
CheckMate 384 (CA209-384)
Appareil pulmonaire
Essai clinique fermé
Public cible
Adulte
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
Description de l'essai
The primary objective of this study is to show that PFS (progress-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks is non-inferior to nivolumab 240 mg every 2 weeks in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non-Sq and Sq).
Liens utiles
![CATHERINE DANIEL Vignette](/sites/default/files/styles/carre_petit/public/annuaire/00001636-65685c73890e4.jpg?h=34e0dbd8&itok=J_RV4T7f)
CATHERINE DANIEL
Investigateur principal